Advertisement

Lung Cancer in Older Adults: Local Treatment

  • Drew Moghanaki
  • Carlos E. Bravo Iñiguez
  • Michael T. Jaklitsch
Living reference work entry

Abstract

Lung cancer is a malignancy that primarily affects the elderly. It is commonly diagnosed in patients with co-morbidiies who may have concerns about complications from aggressive therapies. This chapter is written for the non-oncologist to provide guidance on how best to approach elderly patients with lung cancer. An emphasis is made regarding the value of a multi-disciplinary team-based approach, given the evidence continues to evolve for an optimal approach in many clinical situations. It descirbes the advantages of minimally invasive thoracic surgery that have been reported in randomized clinical trials. It also summarizes the serendipitous outcomes following stereotactic radiotherapy for early stage disease that currently calls into question the time-honored belief that surgery provides the only hope for cure. A section is dedicated to the evoluation of treatment paradigms for patients with locally advanced lung cancer which has led to lower doses and smaller fields of radiotherapy than ever before. Finally, an update is provided regarding management options for localized small cell lung cancer.

References

  1. Armstrong KW, Bravo-Iniguez CE, Jacobson FL, Jaklitsch MT. Recent trends in surgical research of cancer treatment in the elderly, with a primary focus on lung cancer: presentation at the 2015 annual meeting of SIOG. J Geriatr Oncol. 2016;7(5):368–74.CrossRefGoogle Scholar
  2. Auperin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med. 1999;341(7):476–84.CrossRefGoogle Scholar
  3. Baumann P, Nyman J, Hoyer M, et al. Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol. 2009;27(20):3290–6.CrossRefGoogle Scholar
  4. Bendixen M, Jorgensen OD, Kronborg C, Andersen C, Licht PB. Postoperative pain and quality of life after lobectomy via video-assisted thoracoscopic surgery or anterolateral thoracotomy for early stage lung cancer: a randomised controlled trial. Lancet Oncol. 2016;17(6):836–44.CrossRefGoogle Scholar
  5. Berman AT, Rosenthal SA, Moghanaki D, Woodhouse KD, Movsas B, Vapiwala N. Focusing on the “Person” in personalized medicine: the future of patient-centered care in radiation oncology. J Am Coll Radiol. 2016;13(12 Pt B):1571–8.CrossRefGoogle Scholar
  6. Billmeier SE, Ayanian JZ, He Y, Jaklitsch MT, Rogers SO. Predictors of nursing home admission, severe functional impairment, or death one year after surgery for non-small cell lung cancer. Ann Surg. 2013;257(3):555–63.CrossRefGoogle Scholar
  7. Blomgren H, Lax I, Naslund I, Svanstrom R. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. Acta Oncol. 1995;34(6):861–70.CrossRefGoogle Scholar
  8. Bradley J. New territory: surgical salvage for stereotactic body radiation therapy failures in lung cancer. J Thorac Oncol. 2010;5(12):1879–80.CrossRefGoogle Scholar
  9. Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015;16(2):187–99.CrossRefGoogle Scholar
  10. Brunelli A, Salati M, Rocco G, et al. European risk models for morbidity (EuroLung1) and mortality (EuroLung2) to predict outcome following anatomic lung resections: an analysis from the European Society of Thoracic Surgeons database. Eur J Cardiothorac Surg. 2017;51(3):490–497.Google Scholar
  11. Cattaneo SM, Park BJ, Wilton AS, et al. Use of video-assisted thoracic surgery for lobectomy in the elderly results in fewer complications. Ann Thorac Surg. 2008;85(1):231–5; discussion 235–236.CrossRefGoogle Scholar
  12. Cerfolio RJ, Cichos KH, Wei B, Minnich DJ. Robotic lobectomy can be taught while maintaining quality patient outcomes. J Thorac Cardiovasc Surg. 2016;152(4):991–7.CrossRefGoogle Scholar
  13. Chang JY, Li QQ, Xu QY, et al. Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a “no fly zone”. Int J Radiat Oncol Biol Phys. 2014;88(5):1120–8.CrossRefGoogle Scholar
  14. Chang JY, Senan S, Paul MA, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol. 2015;16(6):630–7.CrossRefGoogle Scholar
  15. Corso CD, Park HS, Moreno AC, et al. Stage I Lung SBRT Clinical Practice Patterns. Am J Clin Oncol. 2017;40(4):358–361.CrossRefGoogle Scholar
  16. Crabtree TD, Puri V, Robinson C, et al. Analysis of first recurrence and survival in patients with stage I non-small cell lung cancer treated with surgical resection or stereotactic radiation therapy. J Thorac Cardiovasc Surg. 2014;147(4):1183–91; discussion 1191–1182.CrossRefGoogle Scholar
  17. Craig SR, Leaver HA, Yap PL, Pugh GC, Walker WS. Acute phase responses following minimal access and conventional thoracic surgery. Eur J Cardiothorac Surg. 2001;20(3):455–63.CrossRefGoogle Scholar
  18. Curran WJ Jr, Paulus R, Langer CJ, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011;103(19):1452–60.CrossRefGoogle Scholar
  19. Demmy TL, Curtis JJ. Minimally invasive lobectomy directed toward frail and high-risk patients: a case-control study. Ann Thorac Surg. 1999;68(1):194–200.CrossRefGoogle Scholar
  20. Dickhoff C, Dahele M, de Langen AJ, et al. Population-based patterns of surgical care for stage IIIA NSCLC in the Netherlands between 2010 and 2013. J Thorac Oncol. 2016;11(4):566–72.CrossRefGoogle Scholar
  21. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006;7(9):719–27.CrossRefGoogle Scholar
  22. Faivre-Finn C, Snee M, Ashcroft L, et al. CONVERT: an international randomised trial of concurrent chemo-radiotherapy (cCTRT) comparing twice-daily (BD) and once-daily (OD) radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status (PS). J Clin Oncol. 2016;34(suppl 15):8504.Google Scholar
  23. Fakiris AJ, McGarry RC, Yiannoutsos CT, et al. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys. 2009;75(3):677–82.CrossRefGoogle Scholar
  24. Farjah F, Flum DR, Varghese TK Jr, Symons RG, Wood DE. Surgeon specialty and long-term survival after pulmonary resection for lung cancer. Ann Thorac Surg. 2009;87(4):995–1004; discussion 1005–1006.CrossRefGoogle Scholar
  25. Felip E, Rosell R, Maestre JA, et al. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer. J Clin Oncol. 2010;28(19):3138–45.CrossRefGoogle Scholar
  26. Ferraris VA, Saha SP, Davenport DL, Zwischenberger JB. Thoracic surgery in the real world: does surgical specialty affect outcomes in patients having general thoracic operations? Ann Thorac Surg. 2012;93(4):1041–7; discussion 1047–1048.CrossRefGoogle Scholar
  27. Goodney PP, Lucas FL, Stukel TA, Birkmeyer JD. Surgeon specialty and operative mortality with lung resection. Ann Surg. 2005;241(1):179–84.PubMedPubMedCentralGoogle Scholar
  28. Graham EA, Singer JJ. Successful removal of an entire lung for carcinoma of the bronchus. JAMA. 1933;101:1371–4.CrossRefGoogle Scholar
  29. Guckenberger M, Allgauer M, Appold S, et al. Safety and efficacy of stereotactic body radiotherapy for stage 1 non-small-cell lung cancer in routine clinical practice: a patterns-of-care and outcome analysis. J Thorac Oncol. 2013;8(8):1050–8.CrossRefGoogle Scholar
  30. Haque W, Szeja S, Tann A, Kalra S, Teh BS. Changes in Treatment Patterns and Overall Survival in Patients With Early-Stage Non-Small Cell Lung Cancer in the United States After the Incorporation of Stereotactic Ablative Radiation Therapy: A Population-based Analysis. Am J Clin Oncol. 2018;41(3):259–266.Google Scholar
  31. Hof H, Muenter M, Oetzel D, Hoess A, Debus J, Herfarth K. Stereotactic single-dose radiotherapy (radiosurgery) of early stage nonsmall-cell lung cancer (NSCLC). Cancer. 2007;110(1):148–55.CrossRefGoogle Scholar
  32. Howington JA, Blum MG, Chang AC, Balekian AA, Murthy SC. Treatment of stage I and II non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e278S–313S.CrossRefGoogle Scholar
  33. Huang K, Palma DA. Follow-up of patients after stereotactic radiation for lung cancer: a primer for the nonradiation oncologist. J Thorac Oncol. 2015;10(3):412–9.CrossRefGoogle Scholar
  34. Husain ZA, Kim AW, Yu JB, Decker RH, Corso CD. Defining the high-risk population for mortality after resection of early stage NSCLC. Clin Lung Cancer. 2015;16(6):e183–7.CrossRefGoogle Scholar
  35. Kirby TJ, Mack MJ, Landreneau RJ, Rice TW. Lobectomy – video-assisted thoracic surgery versus muscle-sparing thoracotomy. A randomized trial. J Thorac Cardiovasc Surg. 1995;109(5):997–1001; discussion 1001–1002.CrossRefGoogle Scholar
  36. Komiyama T, Onishi H, Shioyama Y, et al. Japanese multicenter study of stereotactic body radiotherapy for 661 medically operable patients with stage I non-small cell lung cancer. J Thorac Oncol. 2015;10:S210–S1.Google Scholar
  37. Lagerwaard FJ, Verstegen NE, Haasbeek CJ, et al. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2012;83(1):348–53.CrossRefGoogle Scholar
  38. Long H, Lin ZC, Lin YB, Situ DR, Wang YN, Rong TH. Quality of life after lobectomy for early stage non-small cell lung cancer – video-assisted thoracoscopic surgery versus minimal incision thoracotomy. Ai Zheng. 2007a;26(6):624–8.PubMedGoogle Scholar
  39. Long H, Lin ZC, Situ DR, et al. Cytokine responses after lobectomy: a prospective randomized comparison of video-assisted thoracoscopic surgery and minimal incision thoracotomy. Ai Zheng. 2007b;26(9):991–5.PubMedGoogle Scholar
  40. Louie AV, Palma DA, Dahele M, Rodrigues GB, Senan S. Management of early-stage non-small cell lung cancer using stereotactic ablative radiotherapy: controversies, insights, and changing horizons. Radiother Oncol. 2015;114(2):138–147.CrossRefGoogle Scholar
  41. McGarry RC, Song G, des Rosiers P, Timmerman R. Observation-only management of early stage, medically inoperable lung cancer: poor outcome. Chest. 2002;121(4):1155–8.CrossRefGoogle Scholar
  42. McGarry RC, Papiez L, Williams M, Whitford T, Timmerman RD. Stereotactic body radiation therapy of early-stage non-small-cell lung carcinoma: phase I study. Int J Radiat Oncol Biol Phys. 2005;63(4):1010–5.CrossRefGoogle Scholar
  43. McNeil BJ, Weichselbaum R, Pauker SG. Fallacy of the five-year survival in lung cancer. N Engl J Med. 1978;299(25):1397–401.CrossRefGoogle Scholar
  44. Miller AB, Fox W, Tall R. Five-year follow-up of the medical research council comparative trial of surgery and radiotherapy for the primary treatment of small-celled or oat-celled carcinoma of the bronchus. Lancet. 1969;2(7619):501–5.CrossRefGoogle Scholar
  45. Moghanaki D, Chang JY. Is surgery still the optimal treatment for stage I non-small cell lung cancer? Transl Lung Cancer Res. 2016;5(2):183–9.CrossRefGoogle Scholar
  46. Morrison R, Deeley TJ, Cleland WP. The treatment of carcinoma of the bronchus. A clinical trial to compare surgery and supervoltage radiotherapy. Lancet. 1963;281:683–4.CrossRefGoogle Scholar
  47. Nagata Y, Hiraoka M, Shibata T, et al. Prospective trial of stereotactic body radiation therapy for both operable and inoperable T1N0M0 non-small cell lung cancer: Japan clinical oncology group study JCOG0403. Int J Radiat Oncol Biol Phys. 2015;93(5):989–96.CrossRefGoogle Scholar
  48. National Lung Screening Trial Research T, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395–409.CrossRefGoogle Scholar
  49. Neri S, Takahashi Y, Terashi T, et al. Surgical treatment of local recurrence after stereotactic body radiotherapy for primary and metastatic lung cancers. J Thorac Oncol. 2010;5(12):2003–7.CrossRefGoogle Scholar
  50. Onishi H, Shirato H, Nagata Y, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol. 2007;2(7 Suppl 3):S94–100.CrossRefGoogle Scholar
  51. Onishi H, Shirato H, Nagata Y, et al. Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery? Int J Radiat Oncol Biol Phys. 2011;81(5):1352–8.CrossRefGoogle Scholar
  52. Pasini F, Verlato G, Durante E, et al. Persistent excess mortality from lung cancer in patients with stage I non-small-cell lung cancer, disease-free after 5 years. Br J Cancer. 2003;88(11):1666–8.CrossRefGoogle Scholar
  53. Paul S, Lee PC, Mao J, Isaacs AJ, Sedrakyan A. Long term survival with stereotactic ablative radiotherapy (SABR) versus thoracoscopic sublobar lung resection in elderly people: national population based study with propensity matched comparative analysis. BMJ. 2016;354:i3570.CrossRefGoogle Scholar
  54. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26(21):3552–9.CrossRefGoogle Scholar
  55. Rao A, Sharma N, Gajra A. Management of lung cancer in the elderly. Cancer Treat Res. 2016;170:251–84.CrossRefGoogle Scholar
  56. Rosenzweig KE, Sura S, Jackson A, Yorke E. Involved-field radiation therapy for inoperable non small-cell lung cancer. J Clin Oncol. 2007;25(35):5557–61.CrossRefGoogle Scholar
  57. Samson P, Robinson CG, Bradley J, et al. The National Surgical Quality Improvement Program risk calculator does not adequately stratify risk for patients with clinical stage I non-small cell lung cancer. J Thorac Cardiovasc Surg. 2016;151(3):697–705. e691CrossRefGoogle Scholar
  58. Schipper PH, Diggs BS, Ungerleider RM, Welke KF. The influence of surgeon specialty on outcomes in general thoracic surgery: a national sample 1996 to 2005. Ann Thorac Surg. 2009;88(5):1566–72; discussion 1572–1563.CrossRefGoogle Scholar
  59. Senan S. Stereotactic body radiotherapy: do central lung tumors still represent a ‘no-fly zone’? Onkologie. 2012;35(7–8):406–7.CrossRefGoogle Scholar
  60. Senthi S. Use of stereotactic body radiation therapy with salvage surgery to improve outcomes for early stage non-small cell lung cancer. J Thorac Cardiovasc Surg. 2014;148(4):1760.CrossRefGoogle Scholar
  61. Senthi S, Lagerwaard FJ, Haasbeek CJ, Slotman BJ, Senan S. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis. Lancet Oncol. 2012;13(8):802–9.CrossRefGoogle Scholar
  62. Shibamoto Y, Hashizume C, Baba F, et al. Stereotactic body radiotherapy using a radiobiology-based regimen for stage I non-small-cell lung cancer: five-year mature results. J Thorac Oncol. 2015;10(6):960–4.CrossRefGoogle Scholar
  63. Shirvani SM, Jiang J, Chang JY, et al. Lobectomy, sublobar resection, and stereotactic ablative radiotherapy for early-stage non-small cell lung cancers in the elderly. JAMA Surg. 2014;149:1244–53.CrossRefGoogle Scholar
  64. Shorvon LM. Carcinoma of the bronchus with especial reference to its treatment by radiotherapy. Br J Radiol. 1947;20(239):443–9.CrossRefGoogle Scholar
  65. Solberg TD, Balter JM, Benedict SH, et al. Quality and safety considerations in stereotactic radiosurgery and stereotactic body radiation therapy: executive summary. Pract Radiat Oncol. 2012;2(1):2–9.CrossRefGoogle Scholar
  66. Stahl JM, Corso CD, Verma V, et al. Trends in stereotactic body radiation therapy for stage I small cell lung cancer. Lung Cancer. 2017;103:11–6.CrossRefGoogle Scholar
  67. Sugi K, Kaneda Y, Esato K. Video-assisted thoracoscopic lobectomy achieves a satisfactory long-term prognosis in patients with clinical stage IA lung cancer. World J Surg. 2000;24(1):27–30; discussion 30–21.CrossRefGoogle Scholar
  68. Taira N, Kawabata T, Ichi T, et al. Salvage operation for late recurrence after stereotactic body radiotherapy for lung cancer: two patients with no viable cancer cells. Ann Thorac Surg. 2014;97(6):2167–71.CrossRefGoogle Scholar
  69. Timmerman R, Papiez L, McGarry R, et al. Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest. 2003;124(5):1946–55.CrossRefGoogle Scholar
  70. Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA: J Am Med Assoc. 2010;303(11):1070–6.CrossRefGoogle Scholar
  71. Timmerman R, Paulus R, Pass H, et al. RTOG 0618: stereotactic body radiation therapy (SBRT) to treat operable early stage lung cancer patients. J Clin Oncol. 2013;31(suppl):7523; abstr.Google Scholar
  72. Timmerman RD, Hu C, Michalski J, Straube W, Galvin J, Johnstone D, Bradley J, Barriger R, Bezjak A, Videtic GM, Nedzi L, Werner-Wasik M, Chen Y, Komaki RU, Choy H. Long-term results of RTOG 0236: a phase II trial of stereotactic body radiation therapy (SBRT) in the treatment of patients with medically inoperable stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2014;90(1):S30.  https://doi.org/10.1016/j.ijrobp.2014.05.135.CrossRefGoogle Scholar
  73. Timmermann C. As depressing as it was predictable? Lung cancer, clinical trials, and the Medical Research Council in postwar Britain. Bull Hist Med. 2007;81(1):312–34.CrossRefGoogle Scholar
  74. Turrisi AT 3rd, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999;340(4):265–71.CrossRefGoogle Scholar
  75. Uematsu M, Shioda A, Suda A, et al. Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: a 5-year experience. Int J Radiat Oncol Biol Phys. 2001;51(3):666–70.CrossRefGoogle Scholar
  76. Verstegen NE, Maat AP, Lagerwaard FJ, et al. Salvage surgery for local failures after stereotactic ablative radiotherapy for early stage non-small cell lung cancer. Radiat Oncol. 2016;11(1):131.CrossRefGoogle Scholar
  77. Veterans Affairs Lung Cancer Surgery or Stereotactic Radiotherapy (VALOR). (n.d.). http://clinicaltrials.gov/ct2/show/NCT02984761
  78. von Meyenfeldt EM, Gooiker GA, van Gijn W, et al. The relationship between volume or surgeon specialty and outcome in the surgical treatment of lung cancer: a systematic review and meta-analysis. J Thorac Oncol. 2012;7(7):1170–8.CrossRefGoogle Scholar
  79. Wang S, Wong ML, Hamilton N, Davoren JB, Jahan TM, Walter LC. Impact of age and comorbidity on non-small-cell lung cancer treatment in older veterans. J Clin Oncol. 2012;30(13):1447–55.CrossRefGoogle Scholar
  80. Zhang B, Zhu F, Ma X, et al. Matched-pair comparisons of stereotactic body radiotherapy (SBRT) versus surgery for the treatment of early stage non-small cell lung cancer: a systematic review and meta-analysis. Radiother Oncol. 2014;112(2):250–5.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Drew Moghanaki
    • 1
  • Carlos E. Bravo Iñiguez
    • 2
  • Michael T. Jaklitsch
    • 3
  1. 1.Radiation Oncology ServiceHunter Holmes McGuire Veterans Affairs Medical CenterRichmondUSA
  2. 2.Department of Surgery, Division of Thoracic SurgeryBrigham and Women’s Hospital, Harvard Medical SchoolBostonUSA
  3. 3.Department of Surgery, Division of Thoracic SurgeryBrigham and Women’s Hospital/Dana-Farber Cancer InstituteBostonUSA

Section editors and affiliations

  • Etienne Brain
    • 1
  1. 1.Department of Medical Oncology, Institute CurieHôpital René HugueninSaint-CloudFrance

Personalised recommendations